Can i stop taking paxlovid if it makes me sick
Pro Research Analysisby 
Searched over 200M research papers
Can I Stop Taking Paxlovid if It Makes Me Sick?
Introduction to Paxlovid and Its Use
Paxlovid, a combination of nirmatrelvir and ritonavir, has been granted Emergency Use Authorization (EUA) for the treatment of mild to moderate COVID-19 in individuals at high risk for severe disease. Clinical trials have shown that Paxlovid is highly effective in reducing hospitalizations and deaths among high-risk patients2. However, like all medications, it can have side effects and interactions with other drugs.
Common Side Effects and Severe Reactions
Hyponatremia and Paxlovid
Recent case studies have highlighted severe hyponatremia (low sodium levels) in patients taking Paxlovid. In a community hospital, four patients were admitted to the ICU with severe hyponatremia while on Paxlovid. Symptoms included weakness, nausea, and dehydration. The hyponatremia resolved after stopping Paxlovid and administering conventional treatments1. This suggests that while hyponatremia is not a widely recognized side effect, it can occur and may require cessation of the drug.
Drug Interactions Leading to Toxicity
Paxlovid can interact with other medications, leading to severe side effects. For instance, a case involving an adolescent with inflammatory bowel disease (IBD) treated with Paxlovid showed that the drug interaction with tacrolimus led to suspected tacrolimus toxicity. The patient experienced vomiting, fatigue, and headaches, which resolved after stopping tacrolimus and allowing the drug levels to normalize3. This case underscores the importance of monitoring drug interactions and possibly discontinuing Paxlovid if severe reactions occur.
Decision to Stop Taking Paxlovid
Monitoring and Consultation
If Paxlovid causes severe side effects, it is crucial to consult a healthcare provider immediately. The decision to stop taking Paxlovid should be made under medical supervision, especially considering its effectiveness in preventing severe COVID-19 outcomes2. Healthcare providers can assess the severity of side effects and determine the best course of action, which may include stopping the medication or adjusting the treatment plan.
Importance of Drug Interaction Checkers
Using tools like the Liverpool COVID-19 interaction checker can help identify potential drug interactions before starting Paxlovid. This proactive approach can prevent severe side effects and ensure safer use of the medication1.
Conclusion
While Paxlovid is effective in reducing severe COVID-19 outcomes, it can cause significant side effects and interact with other medications. If you experience severe side effects, consult your healthcare provider to determine whether you should stop taking Paxlovid. Monitoring and managing drug interactions are essential to minimize risks and ensure the safe use of this medication.
Sources and full results
Most relevant research papers on this topic
1082: SPIKE IN CRITICAL CARE ADMISSIONS FOR SEVERE HYPONATREMIA IN PATIENTS RECEIVING PAXLOVID
Paxlovid may cause severe hyponatremia in COVID-19 patients, warranting further investigation and vigilant review of concomitant medications using the Liverpool interaction checker.
Case ReportCovid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports
Paxlovid is 89% effective in reducing hospital admissions and deaths in Covid-19 patients, with no deaths observed in the study.
RCT
Large Human Trial
Rigorous Journal
Highly CitedDRUG INTERACTION BETWEEN PAXLOVID AND TACROLIMUS IN AN ADOLESCENT WITH INFLAMMATORY BOWEL DISEASE
Paxlovid and tacrolimus drug interaction can cause toxicity in adolescents with inflammatory bowel disease, requiring careful monitoring.
Case ReportPaxlovid-Induced Symptomatic Bradycardia and Syncope
Paxlovid, a COVID-19 treatment, may cause symptomatic bradycardia and syncope, and prompt discontinuation and intravenous atropine can help reverse these symptoms.
Case ReportClinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant
Paxlovid is a safe and effective treatment for children 12 years old and younger with underlying hematological diseases infected with the new coronavirus, with no apparent adverse reactions.
Observational StudyRanolazine Toxicity Secondary to Paxlovid
Paxlovid may cause ranolazine toxicity in patients who continue to take it at home, but the patient recovered after 54 hours and returned to baseline.
Case ReportEffectiveness of Paxlovid, an Oral Antiviral Drug, Against the Omicron BA.5 Variant in Korea: Severe Progression and Death Between July and November 2022
Paxlovid effectively reduces the risk of death due to COVID-19 in patients with omicron BA.5 infection, especially in older patients, regardless of vaccination status.
Observational StudySafety and Efficacy of Paxlovid in COVID-19 Treatment: A Rapid Review
Paxlovid is an effective outpatient treatment for mild to moderate COVID-19 symptoms, but drug interactions remain uncertain.
Systematic ReviewCholesterol-lowering drugs for high-risk hypercholesterolemia patients with COVID-19 while on Paxlovid™ therapy
Paxlovid therapy for COVID-19 patients with severe hypercholesterolemia should be combined with statin treatment, but statins should be substituted or reduced during Paxlovid treatment.
The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial
Paxlovid significantly reduces the nucleic acid shedding time in Chinese elder patients infected with SARS-CoV-2 omicron variants.
RCT